News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Ends Celebrex Post-approval Safety Study Because of Difficulty Finding Patients


3/12/2012 7:43:44 AM

Pfizer Inc. said Friday it is ending a safety study of its pain drug Celebrex because of difficulty finding patients. The trial was designed to measure the effects of Celebrex on patients who were taking the drug to treat juvenile idiopathic arthritis. Pfizer said it was having trouble enrolling patients in the trial, and the study was not likely to produce meaningful results because patients with the condition tend to use Celebrex for a short time and because the rate of side effects was very low. Sales of Celebrex grew 6 percent to $2.52 billion in 2011, which made it Pfizer's fifth-best-selling drug. It was originally approved in 1998, and Pfizer was required to do the safety study in 2006 after Celebrex was approved as a treatment for juvenile idiopathic arthritis.

Read at CBS News
Read at Fox News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES